Cardiometabolic News and Research

RSS

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Xenon founder receives Canada Wightman Award for leadership in medical science

Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada.

23 Mar 2011

NYC expands YMCA's Diabetes Prevention Program to help adults avoid disease consequences

The YMCA of Greater New York today announced the New York City expansion of the YMCA's Diabetes Prevention Program, a 16-session group behavior change class that helps people at high risk for developing type 2 diabetes prevent the disease through healthy eating, increased activity and other positive lifestyle changes.

22 Mar 2011

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.

22 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

Atherotech announces Sponsorship Agreement with NLA

Aiming to boost advanced lipoprotein testing in lipid education and management, Atherotech Diagnostics Lab announces its Sponsorship Agreement with the National Lipid Association.

9 Mar 2011

Study: Role of air pollutants in cardiometabolic syndrome

To explore one of the most critical health/environment intersections - how the very air we breathe can cause heart disease and diabetes and contribute to the problems of obesity - Michigan State University has been named a Clean Air Research Center by the Environmental Protection Agency.

8 Mar 2011

Study: Overweight adolescents may have high risk of less bone mass

Overweight adolescents already struggling with risk factors such as insulin resistance may need to add weak bones to their list of health concerns, researchers report.

5 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

Experts at ICAO warn about risk of cardiometabolic consequences in overweight individuals

Experts meeting at the 2nd International Congress on Abdominal Obesity today issued a warning that millions of individuals around the globe are at risk from the cardiometabolic consequences of being overweight. Worryingly, the experts suggest that these people are not being identified by their doctors.

25 Feb 2011

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.

8 Feb 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

Transition of oncology programme into lead optimisation triggers EUR 2.0M milestone payment to Evotec

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec.

13 Jan 2011

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.

29 Dec 2010

Merck, sanofi-aventis enter global cancer research and development agreement

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Merck, has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells. This collaboration could deliver novel targeted oncology treatments with high therapeutic potential.

17 Dec 2010

Common sleep complaints predict development of metabolic syndrome: Study

A study in the Dec. 1 issue of the journal SLEEP found that loud snoring and two common insomnia symptoms difficulty falling asleep and unrefreshing sleep each significantly predicted the development of the metabolic syndrome. The study emphasizes the importance of screening for common sleep complaints in routine clinical practice.

1 Dec 2010

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune Technologies & Bioressources Inc. subsidiary, Acasti Pharma Inc., reports the completion of its preclinical program designed to compare the lipid management effects of Acasti's drug candidate CaPre versus prescription drug Lovaza.

25 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.

22 Nov 2010